Next Generation Protein Engineering and Drug Design

  • ABOUT THE AUTHOR
    • Biophoenix
    • DISCLAIMER
  • EXECUTIVE SUMMARY
    • Engineering next generation protein drugs
    • Strategies and technologies for protein engineering
    • Engineering improved monoclonal antibodies
    • Engineering alternatives to antibodies
    • Engineering other protein and peptide drugs
    • Engineering protein therapeutics for delivery
    • Trends and opportunities
  • ENGINEERING NEXT GENERATION PROTEIN DRUGS
    • Summary
    • Introduction
    • Background on proteins
    • Patenting of proteins
    • Regulatory requirements
    • Commercial imperatives in protein engineering
      • Introduction
      • Application markets
      • Manufacturer markets
      • Product markets
      • Geographical markets
      • Patenting considerations
      • Analysis by assignee patent count
      • Analysis by forward citation count
    • Commercial outlook for engineered proteins
  • STRATEGIES AND TECHNOLOGIES FOR PROTEIN ENGINEERING
    • Summary
    • Introduction
    • Recombinant protein production
      • Site-directed mutagenesis
    • Post-translational modifications (PTMs)
      • Glycosylation of natural proteins
      • Manufacture of glycoproteins
      • Glyco-remodeling
      • Other PTMs
    • Protein characterization
    • Directed evolution
      • Display technologies
      • Use of protein scaffolds
    • Peptide and protein synthesis
      • Chemoselective ligation
    • In silico protein design
    • Technology-related patents
      • Monoclonal antibodies
      • Other proteins and peptides
  • ENGINEERING IMPROVED MONOCLONAL ANTIBODIES
    • Summary
    • Natural antibodies
      • Human IgG
      • Generation of antibody diversity
    • Monoclonal antibodies
      • Evolution of mAbs
      • Drivers for innovation
    • The mAb business landscape
      • Products on the US market
      • Products in development
    • Improving mAb production systems
      • Cell lines
      • Automation
    • Manipulating mAb glycosylation profiles
    • Enhancing mAb serum stability
    • Engineering fully human mAbs
      • Human mAbs from recombinant antibody libraries
      • Human mAbs from transgenic mice and chickens
      • Human mAbs on the market and in development
    • Engineering novel antibody fragments
      • Monovalent fragments
      • Multivalent fragments
      • Fragments on the market and in development
    • Engineering for specific therapeutic applications
      • Cancer
      • Immune and inflammatory disorders
      • Other areas
  • ENGINEERING ALTERNATIVES TO ANTIBODIES
    • Summary
    • Introduction
    • Comparison with monoclonal antibodies
    • Combinatorial scaffold libraries
      • Scaffolds used in library construction
      • Scaffold optimization and diversification
      • Selection technologies
    • Recognition proteins as therapeutics
      • Products in commercial development
  • ENGINEERING OTHER PROTEIN AND PEPTIDE DRUGS
    • Summary
    • Introduction to protein/peptide drugs
      • Drivers for innovation
    • The business landscape
      • Products on the market and in development
    • Improving production systems
      • Recombinant methods
      • Transgenic methods
      • Chemical methods
      • Tackling immunogenicity
    • Manipulating PTMs
      • Glycoprotein profiling
      • Glyco-engineering
      • Other PTMs
    • Altering plasma half-lives
      • Amino acid modifications
      • Variations in glycosylation
      • PEGylation
      • Chemical modification
      • Other novel approaches
      • Case study: Erythropoiesis-stimulating agents
    • Expediting peptide drug discovery
      • Phage and other display technologies
      • Rational design
      • Case study: Antimicrobial peptide discovery
    • Exploring the role of pharmacogenomics
  • ENGINEERING PROTEIN THERAPIES FOR DELIVERY
    • Summary
    • Introduction
    • Injectable protein delivery
      • Half-life extension technologies
      • Depot systems
    • Pulmonary delivery
      • Exubera (inhalable recombinant insulin)
      • Alkermes' AIR dry powder
      • Aradigm's AERx system
      • Baxter Healthcare's Promaxx technology
      • Syntonix Pharmaceuticals' Fc Fusion Proteins
    • Nasal delivery
    • Oral and other forms of delivery
      • Cell penetrating peptides and polymeric nanoparticles
    • Other approaches
      • Affinergy
  • TRENDS AND OPPORTUNITIES
    • Summary
    • Creating non-immunogenic monoclonal antibodies
    • The next wave of monoclonal antibody-based agents
    • Beyond monoclonal antibodies
    • The challenge of follow-on biologics
    • The promise of synthetic peptides and proteins
    • New frontier: de novo protein design
  • APPENDIX
    • Index
  • TABLES
    • Table: World pharma market by indication, 2011
    • Table: Protein engineering markets by application, 2011
    • Table: mAb protein engineering markets by company, 2006 - 2011
    • Table: Non-mAb protein engineering markets by company, 2011
    • Table: Total protein engineering markets by company, 2011
    • Table: Protein Engineering Markets by Product, 2006
    • Table: Protein engineering markets by product, 2011
    • Table: World Pharma Market by Region, 2011
    • Table: Protein Engineering Market by Region, 2006 - 2011
    • Table: US patent codes dealing with antibody related subject matter
    • Table: Protein engineering US patents and published applications by leading assignees
    • Table: Top 50 protein engineering patent assignees by forward citation count
    • Table: Fully human engineered immunoglobulin patents: US filings, 1992-2006
    • Table: Launched mAb products, 2006
    • Table: Phase 3 mAb products, 2006
    • Table: Phase 2 mAb products, 2006
    • Table: Phase 1 mAb products, 2006
    • Table: Pre-clinical mAb products by name, 2006
    • Table: Non-immunoglobulin binding proteins in development
    • Table: Examples of launched engineered human recombinant therapeutic proteins
    • Table: Examples of launched engineered human recombinant therapeutic proteins continued.
    • Table: Therapeutic human proteins produced in animal bioreactors: products in development
    • Table: Engineered small peptide and peptidomimetic drugs: examples from antimicrobial R&D
    • Table: Injectable protein delivery: half-life extension technologies
    • Table: Injectable protein delivery: depot technologies
    • Table: Top 50 Cited Protein Engineering Patents (US Filings, 1992-2006)
  • FIGURES
    • Figure: US protein engineering patents and published applications by filing and publication years, 1992-2006
    • Figure: Protein scaffold used to create designer protein drugs
    • Figure: Protein engineering patents: technologies and applications
    • Figure: Innovators in therapeutic protein production

Report

Published by
Business Insights
Published on
23 Feb 2007
Product code
BI00020-004
Pages
Please wait...

$2875

Multi-user License $10781